[HTML][HTML] Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology & …, 2022 - search.proquest.com
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
[HTML][HTML] Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology & …, 2022 - jhoonline.biomedcentral.com
Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of
cholangiocarcinoma. The main challenges for an effective immunotherapy response in …
cholangiocarcinoma. The main challenges for an effective immunotherapy response in …
[HTML][HTML] Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology & …, 2022 - ncbi.nlm.nih.gov
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology and …, 2022 - pure.johnshopkins.edu
Background: Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology & …, 2022 - europepmc.org
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
T Xia, K Li, N Niu, Y Shao, D Ding… - … of hematology & …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
[PDF][PDF] Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
H Jing, K Fujiwara, H Hu, A Osipov, C Yuan… - 2022 - jhoonline.biomedcentral.com
Background: Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
T Xia, K Li, N Niu, Y Shao, D Ding… - … of Hematology & …, 2022 - europepmc.org
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …